Table 3 Univariable and multivariable analysis of the risk of neurological diseases after exposure to COVID-19 vaccines, COVID-19 symptoms or flu symptoms.
Variable | Cases (n = 265) | Controls (n = 265) | OR | 95% CI | p | Adj. OR* | 95% CI | p | ||
|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||||
At least one dose of any COVID-19 vaccine | ||||||||||
No | 74 | 27.9 | 54 | 20.4 | 1 (ref.) | 0.0114 | 1 (ref.) | 0.1343 | ||
Yes | 191 | 72.1 | 211 | 79.6 | 0.50 | 0.29–0.86 | 0.63 | 0.35–1.15 | ||
Number of COVID-19 vaccine doses (any vaccine) | ||||||||||
0 | 74 | 27.9 | 53 | 20.0 | 1 (ref.) | 0.0030 | 1 (ref.) | 0.0862 | ||
1 | 48 | 18.1 | 39 | 14.7 | 0.68 | 0.35–1.30 | 0.77 | 0.37–1.58 | ||
2 | 129 | 48.7 | 149 | 56.2 | 0.40 | 0.22–0.72 | 0.54 | 0.28–1.03 | ||
3+ | 14 | 5.3 | 24 | 9.1 | 0.18 | 0.06–0.52 | 0.23 | 0.07–0.79 | ||
At least one dose of BNT162b2 | ||||||||||
No | 133 | 50.2 | 112 | 42.3 | 1 (ref.) | 0.0456 | 1 (ref.) | 0.4608 | ||
Yes | 132 | 49.8 | 153 | 57.7 | 0.68 | 0.46–0.99 | 0.85 | 0.55–1.30 | ||
At least one dose of mRNA-1273 | ||||||||||
No | 244 | 92.1 | 244 | 92.1 | 1 (ref.) | 1.0000 | 1 (ref.) | 0.6080 | ||
Yes | 21 | 7.9 | 21 | 7.9 | 1.00 | 0.55–1.83 | 0.82 | 0.39–1.72 | ||
At least one dose of ChAdOx1 nCoV-19 | ||||||||||
No | 226 | 85.3 | 225 | 84.9 | 1 (ref.) | 0.8946 | 1 (ref.) | 0.5204 | ||
Yes | 39 | 14.7 | 40 | 15.1 | 0.96 | 0.57–1.62 | 0.82 | 0.46–1.48 | ||
At least one dose of Ad.26.COV2.S | ||||||||||
No | 258 | 97.4 | 257 | 97.0 | 1 (ref.) | 0.7817 | 1 (ref.) | 0.8695 | ||
Yes | 7 | 2.6 | 8 | 3.0 | 0.86 | 0.29–2.55 | 0.90 | 0.26–3.16 | ||
COVID-19 symptoms | ||||||||||
No | 226 | 85.3 | 227 | 85.7 | 1 (ref.) | 0.9013 | 1 (ref.) | 0.9296 | ||
Yes | 39 | 14.7 | 38 | 14.3 | 1.03 | 0.63–1.68 | 0.97 | 0.55–1.74 | ||
Flu symptoms | ||||||||||
No | 263 | 99.2 | 265 | 100.0 | 1 (ref.) | 0.9868 | 1 (ref.) | 0.9854 | ||
Yes | 2 | 0.8 | 0 | 0.0 | ne | ne | ne | ne | – | |
